GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Valuation Rank

HUTCHMED (China) (HUTCHMED (China)) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


HUTCHMED (China) Valuation Rank Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


HUTCHMED (China) (HUTCHMED (China)) Business Description

Traded in Other Exchanges
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.